Abstract:Overexpression of ATP binding cassette (ABC) transporters, including P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), is an important factor leading to multidrug resistance (MDR) in cancer treatments. Three subclasses of dual inhibitors of P-gp and BCRP were designed based on the active moieties of BCRP inhibitors, tyrosine kinase inhibitors, and P-gp inhibitors, of which compound 21 possessed low cytotoxicity, high reversal potency, and good lipid distribution coefficient. 21 also increased the accumulation of Adriamycin (ADM) and Mitoxantrone (MX), blocked Rh123 efflux, and made no change in the protein expression of P-gp and BCRP. Importantly, coadministration of 21 can significantly improve the oral bioavailability of paclitaxel (PTX). It was also demonstrated that 21 significantly inhibited the growth of K562/A02 xenograft tumors by increasing the sensitivity of ADM in vivo. In summary, 21 has the potential to overcome MDR caused by P-gp and BCRP and to improve the oral bioavailability of PTX.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00246?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00246</a>.1H and 13C NMR spectra, ESI-MS, infrared spectra, and UHPLC chromatograms of compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00246/suppl_file/jm1c00246_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00246/suppl_file/jm1c00246_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Discovery to Solve Multidrug Resistance: Design, Synthesis, and Biological Evaluation of Novel Agents

6,7-Dimethoxy-2-{2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as superior reversal agents for P-glycoprotein-mediated multidrug resistance.

Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1h)yl)ethyl)phenyl)quinazolin-4- Amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance

Design, Synthesis and Biological Evaluation of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamide Derivatives As Novel P-glycoprotein Inhibitors Reversing Multidrug Resistance

Design, Synthesis and Biological Evaluation of Novel Triazole-Core Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance

Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety As Orally Bioavailable Reversal Agents Against P-Glycoprotein-Mediated Mutidrug Resistance.

Discovery of aromatic amides with triazole-core as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives As Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance.

Development of a Novel Quinoline Derivative As a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells

Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as potent reversal agents against ABCB1-mediated multidrug resistance

Novel pyxinol amide derivatives bearing an aliphatic heterocycle as P-glycoprotein modulators for overcoming multidrug resistance

Synthesis and Evaluation of Substituted Dibenzo[c,e]azepine-5-ones As P-glycoprotein-mediated Multidrug Resistance Reversal Agents

Discovery of 2,5-disubstituted furan derivatives featuring a benzamide motif for overcoming P-glycoprotein mediated multidrug resistance in MCF-7/ADR cell

Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell

Design, Synthesis and Biological Evaluation of Novel Tetrahydroisoquinoline Derivatives As P-glycoprotein-mediated Multidrug Resistance Inhibitors.

Design, Synthesis and Biological Evaluation of LBM-A5 Derivatives As Potent P-glycoprotein-mediated Multidrug Resistance Inhibitors.

Design, Synthesis and Evaluation of a Novel Series of Inhibitors Reversing P‐glycoprotein‐mediated Multidrug Resistance

Structure-Based Discovery of Pyrimidine Aminobenzene Derivatives as Potent Oral Reversal Agents against P-gp- and BCRP-Mediated Multidrug Resistance

Designed P-glycoprotein Inhibitors with Triazol-Tetrahydroisoquinoline-core Increase Doxorubicin-Induced Mortality in Multidrug Resistant K562/A02 Cells.

Discovery of Novel P-glycoprotein-mediated Multidrug Resistance Inhibitors Bearing Triazole Core Via Click Chemistry.